Company Overview and News
KUALA LUMPUR (Oct 2): AllianceDBS Research said Ikhmas Jaya Group Bhd (Ikhmas) had on Oct 1 traded marginally higher to 26 sen before closing near the day’s low at 24.5 sen (down 0.5 sen or 2.00%).
KUALA LUMPUR (Oct 1): The FBM KLCI notched up limited gains at the midday break today as decliners overtook advancers, against the backdrop of mixed regional markets.
APEXF 7084 7090 BATS 4162 0082 1163 5268 5256 6033 5199 0020 5843 0176 PNADF 1201 3301 7108 1899 2836 HIPEF PNAGF
KUALA LUMPUR (Oct 1): The FBM KLCI pared some of its gains at mid-morning, keeping the local index subdued in line with the regional markets on the first trading day of the fourth quarter.
APEXF 7090 BATS 4162 2089 5256 9334 5199 5008 5843 1201 3026 3301 3867 2836 HIPEF PNAGF 7084 UPBMF 5681 5268 6033 PNADF 0026 1899
KUALA LUMPUR: Cypark Resources Bhd , Comfort Gloves Bhd , Ikhmas Jaya Group Bhd, Gamuda Bhd and LB Aluminium Bhd are among the stocks to watch, according to JF Apex Research.
2127 9326 5184 5268
KUALA LUMPUR (Oct 1): The FBM KLCI is expected to commence the final quarter of 2018 on a subdued note today as market participants await more directions from finance minister Lim Guan Eng when he tables Budget 2019 on Nov 2.
4634 5843 2127 7158 0083 5184 5268 8583 5256
KUALA LUMPUR (Sept 28): Based on corporate announcements and news flow today, companies in focus on Monday (Oct 1) may include: Notion VTec Bhd, IRIS Corp Bhd, Sapura Energy Bhd, Mah Sing Group Bhd, Scomi Group Bhd, Pos Malaysia Bhd, Reach Energy Bhd, Cypark Resources Bhd, Comfort Gloves Bhd, Gamuda Bhd, Kumpulan Perangsang Selangor Bhd (KPS), Berjaya Corp Bhd (BCorp), My EG Services Bhd (MyEG) and Ikhmas Jaya Group Bhd.
4634 5843 2127 7158 0083 5184 5268 8583 5256
KUALA LUMPUR (Sept 28): Piling specialist Ikhmas Jaya Group Bhd has once again postponed the construction of its new prefabricated building system manufacturing facility in Teluk Panglima Garang, Selangor.
BSMAF 5268 1818
KUALA LUMPUR (Aug 16): Ikhmas Jaya Group Bhd is taking property developer ASM Development (KL) Sdn Bhd to court over an outstanding sum of RM14.58 million for contractual work done.
Ikhmas Jaya Group Bhd (-ve) Trading of the shares in Ikhmas Jaya Group Bhd (fundamental: 0.6/3, valuation: 2/3), which triggered our momentum algorithm yesterday for the first time this year, pushed the stock up one sen or 3.12% to 33 sen. The counter saw 12.24 million shares traded, significantly more than its 200-day average trading volume of 672,091.5 shares.
KUALA LUMPUR (July 19): Construction and property stocks have rebounded amid increasing likelihood that the Kuala Lumpur-Singapore High Speed Rail (HSR) project is only deferred and not cancelled.
9571 1589 5268
KUALA LUMPUR (July 19): Shares of Ikhmas Jaya Group Bhd rose 8% this morning after the company, via its wholly-owned subsidiary Ikhmas Jaya Sdn Bhd, bagged a subcontract worth RM78 million for the construction of a marine bridge under the Seri Tanjung Pinang development in Penang, from Kerjaya Prospek (M) Sdn Bhd.
KUALA LUMPUR: JF Apex Research expects Ranhill Holdings Bhd , Hua Yang Bhd , Ikhmas Jaya Group Bhd and Tek Seng Holdings Bhd to be among the stocks to watch following their latest news.
5062 5272 5268 7200
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...